Significance of Pulmonary Arterial Pressure and Diffusion Capacity of the Lung As Prognosticator in Patients with Idiopathic Pulmonary Fibrosis
Overview
Authors
Affiliations
Study Objectives: To evaluate the long-term clinical course of patients with idiopathic pulmonary fibrosis (IPF) complicated with pulmonary arterial hypertension.
Design: Prospective analysis of consecutive IPF patients undergoing initial workup with right-heart catheterization (RHC) and pulmonary function testing (PFT). Pulmonary arterial pressure (PAP) and diffusion capacity of the lung for carbon monoxide (Dlco) were focused on.
Setting: University hospital.
Patients: Seventy-eight patients with IPF (67 men, 11 women; diagnosis by pathology, n = 59; clinical diagnosis, n = 19) had been followed up after initial workup for a maximum of 14 years.
Measurements And Results: RHC data on 61 patients and PFT data on 52 patients were available. Five-year survival rates were 62.2% in the normal-PAP group (mean PAP < 17 mm Hg, n = 37) and 16.7% in the high-PAP group (mean PAP > 17 mm Hg, n = 24) [p < 0.001]; 70.4% in the preserved-Dlco group (percentage of predicted > 40%, n = 27) and 20.0% in the low-Dlco group (percentage of predicted < 40%, n = 25) [p < 0.001]; and 82.6% in group 1 (normal PAP and preserved Dlco, n = 23) and 15.6% in group 2 (high PAP, low Dlco, or both, n = 32) [p < 0.0001]. The relative risks of mortality within 5 years after RHC were 2.20 (95% confidence interval [CI], 1.40 to 3.45) in the high-PAP group, 2.70 (95% CI, 1.46 to 4.99) in the low-Dlco group, and 4.85 (95% CI, 1.97 to 11.97) in group 2.
Conclusion: Dlco was a critical factor for evaluating disease status and prognosis, and PAP status provided feasible information in the initial workup of IPF patients.
Liao Y, Wu B Biomed Rep. 2025; 22(4):58.
PMID: 39991007 PMC: 11843187. DOI: 10.3892/br.2025.1936.
Martinez-Puig P, Baez-Gutierrez N, Rodriguez-Ramallo H, Abdelkader-Martin L, Otero-Candelera R PLoS One. 2025; 20(2):e0318739.
PMID: 39937727 PMC: 11819518. DOI: 10.1371/journal.pone.0318739.
Vitulo P, Piccari L, Wort S, Shlobin O, Kovacs G, Vizza C Pulm Circ. 2024; 14(4):e70005.
PMID: 39659477 PMC: 11629413. DOI: 10.1002/pul2.70005.
Diagnosis and Management of Pulmonary Hypertension: New Insights.
Ntiloudi D, Kasinos N, Kalesi A, Vagenakis G, Theodosis-Georgilas A, Rammos S Diagnostics (Basel). 2024; 14(18).
PMID: 39335731 PMC: 11431164. DOI: 10.3390/diagnostics14182052.
Heresi G, Dean B, Wu B, Lee H, Sketch M, Stafkey-Mailey D BMC Pulm Med. 2024; 24(1):335.
PMID: 38992626 PMC: 11242015. DOI: 10.1186/s12890-024-03141-3.